Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.
作者信息
Mueller Markus, de la Peña Amparo, Derendorf Hartmut
机构信息
Department of Pharmaceutics, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
出版信息
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004.
Abstract
摘要
相似文献
1
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC.抗感染药物的药代动力学和药效学问题：杀菌曲线与最低抑菌浓度
Antimicrob Agents Chemother. 2004 Feb;48(2):369-77. doi: 10.1128/AAC.48.2.369-377.2004.
2
Pharmacodynamics of the new fluoroquinolone gatifloxacin in murine thigh and lung infection models.新型氟喹诺酮类药物加替沙星在小鼠大腿和肺部感染模型中的药效学
Antimicrob Agents Chemother. 2002 Jun;46(6):1665-70. doi: 10.1128/AAC.46.6.1665-1670.2002.
3
Limitations of MIC as the sole criterion in antimicrobial drug dosage regimen design: the need for full characterization of antimicrobial pharmacodynamic profile especially for drug-resistant organisms.将最低抑菌浓度（MIC）作为抗菌药物剂量方案设计的唯一标准的局限性：需要全面描述抗菌药物的药效学特征，尤其是针对耐药菌。
Vet J. 2013 Oct;198(1):15-8. doi: 10.1016/j.tvjl.2013.07.034. Epub 2013 Aug 11.
4
[Tosufloxacin tosilate].[妥舒沙星甲苯磺酸盐]
Jpn J Antibiot. 1990 Apr;43(4):583-602.
5
Animal model pharmacokinetics and pharmacodynamics: a critical review.动物模型的药代动力学和药效学：批判性综述。
Int J Antimicrob Agents. 2002 Apr;19(4):261-8. doi: 10.1016/s0924-8579(02)00022-5.
6
[Fluoroquinolones--antibacterial activity, pharmacokinetics and indications for a new group of chemotherapeutic drugs].[氟喹诺酮类——一类新型化疗药物的抗菌活性、药代动力学及适应证]
Internist (Berl). 1989 Jan;30(1):20-31.
7
ESGAB breakpoint determination: temafloxacin.ESGAB断点确定：替马沙星。
Eur J Clin Microbiol Infect Dis. 1991 Nov;10(11):991-2. doi: 10.1007/BF02005465.
8
In vitro and in vivo antibacterial activities of broad spectrum quinolones against clinical bacterial isolates.广谱喹诺酮类药物对临床分离细菌的体外和体内抗菌活性。
Drugs. 1995;49 Suppl 2:219-21. doi: 10.2165/00003495-199500492-00047.
9
Fluoroquinolone resistance: mechanisms and epidemiology.氟喹诺酮耐药性：机制与流行病学
J Med Microbiol. 1997 Jun;46(6):457-61.
10
[Quinolones. Gyrase inhibitors].[喹诺酮类。回旋酶抑制剂]
Internist (Berl). 1994 May;35(5):484-9.
引用本文的文献
1
Effect of host microenvironment and bacterial lifestyles on antimicrobial sensitivity and implications for susceptibility testing.宿主微环境和细菌生存方式对抗菌敏感性的影响及其对药敏试验的意义。
NPJ Antimicrob Resist. 2025 May 21;3(1):42. doi: 10.1038/s44259-025-00113-3.
2
Jelleine-I Membrane Interaction-related Biological Properties and Antimicrobial Activity against MDR, XDR, and PDR- Clinical Isolates.杰列奈因-I与膜相互作用相关的生物学特性及对多重耐药、广泛耐药和泛耐药临床分离株的抗菌活性
ACS Omega. 2025 Mar 11;10(11):10938-10948. doi: 10.1021/acsomega.4c09073. eCollection 2025 Mar 25.
3
Interspecies interactions alter the antibiotic sensitivity of .种间相互作用会改变……的抗生素敏感性。 （原文表述不完整，此处“.”指代不明）
Microbiol Spectr. 2024 Nov 4;12(12):e0201224. doi: 10.1128/spectrum.02012-24.
4
Adjuvants restore colistin sensitivity in mouse models of highly colistin-resistant isolates, limiting bacterial proliferation and dissemination.佐剂恢复了高度耐粘菌素分离株的粘菌素敏感性，限制了细菌的增殖和传播。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0067124. doi: 10.1128/aac.00671-24. Epub 2024 Aug 28.
5
Investigating the translational value of Periprosthetic Joint Infection (PJI) models to determine the risk and severity of Staphylococcal biofilms.研究人工关节周围感染（PJI）模型的转化价值，以确定葡萄球菌生物膜的风险和严重程度。
bioRxiv. 2024 Jun 12:2024.04.29.591689. doi: 10.1101/2024.04.29.591689.
6
The microbial-derived bile acid lithocholate and its epimers inhibit growth and pathogenicity while sparing members of the gut microbiota.微生物衍生的胆汁酸石胆酸及其差向异构体抑制 生长和致病性，同时不影响肠道微生物群的成员。
J Bacteriol. 2023 Sep 26;205(9):e0018023. doi: 10.1128/jb.00180-23. Epub 2023 Sep 11.
7
Alternate Antimicrobial Therapies and Their Companion Tests.替代抗菌疗法及其配套检测
Diagnostics (Basel). 2023 Jul 26;13(15):2490. doi: 10.3390/diagnostics13152490.
8
Rapid In Vitro Assessment of Antimicrobial Drug Effect Bridging Clinically Relevant Pharmacokinetics: A Comprehensive Methodology.抗菌药物疗效的快速体外评估与临床相关药代动力学的衔接：一种综合方法
Pharmaceutics. 2023 Jun 7;15(6):1671. doi: 10.3390/pharmaceutics15061671.
9
The microbial derived bile acid lithocholate and its epimers inhibit growth and pathogenicity while sparing members of the gut microbiota.微生物衍生的胆汁酸石胆酸及其差向异构体可抑制生长和致病性，同时对肠道微生物群成员无不良影响。
bioRxiv. 2023 Jun 7:2023.06.06.543867. doi: 10.1101/2023.06.06.543867.
10
Implementing best practices on data generation and reporting of assays within the ERA4TB consortium.在ERA4TB联盟内实施关于检测数据生成和报告的最佳实践。
iScience. 2023 Mar 15;26(4):106411. doi: 10.1016/j.isci.2023.106411. eCollection 2023 Apr 21.
本文引用的文献
1
The rate of bactericidal action of penicillin in vitro as a function of its concentration, and its paradoxically reduced activity at high concentrations against certain organisms.青霉素在体外的杀菌作用速率与其浓度的关系，以及在高浓度时对某些生物体其活性反常降低的情况。
J Exp Med. 1948 Jul;88(1):99-131. doi: 10.1084/jem.88.1.99.
2
Pharmacokinetic and pharmacodynamic modelling of antibiotic therapy.抗生素治疗的药代动力学和药效学建模。
Curr Opin Infect Dis. 1998 Dec;11(6):673-80. doi: 10.1097/00001432-199812000-00005.
3
Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.糖肽类药物在肺炎链球菌或金黄色葡萄球菌感染小鼠腹膜炎模型中的药效学。
Antimicrob Agents Chemother. 2000 May;44(5):1247-54. doi: 10.1128/AAC.44.5.1247-1254.2000.
4
Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers.健康志愿者持续输注和静脉推注头孢匹罗后的靶位浓度。
Clin Pharmacol Ther. 2000 Mar;67(3):229-36. doi: 10.1067/mcp.2000.104266.
5
Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.格雷帕沙星与克拉霉素清除慢性支气管炎患者痰液中潜在细菌病原体能力的比较：药代动力学和药效学变量的影响
J Antimicrob Chemother. 2000 Mar;45:9-17. doi: 10.1093/jac/45.suppl_2.9.
6
A retrospective analysis of pharmacokinetic/pharmacodynamic indices as indicators of the clinical efficacy of ciprofloxacin.环丙沙星临床疗效指标的药代动力学/药效学指标回顾性分析
J Antimicrob Chemother. 2000 Mar;45(3):321-8. doi: 10.1093/jac/45.3.321.
7
Antimicrobial action and pharmacokinetics/pharmacodynamics: the use of AUIC to improve efficacy and avoid resistance.抗菌作用及药代动力学/药效学：运用AUIC提高疗效并避免耐药性。
J Chemother. 1999 Dec;11(6):426-39. doi: 10.1179/joc.1999.11.6.426.
8
Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy.药物给药方式的药效学方面，以优化药物治疗。
Crit Rev Ther Drug Carrier Syst. 1999;16(6):571-639.
9
Potential role of pharmacokinetics, pharmacodynamics, and computerized databases in controlling bacterial resistance.药代动力学、药效学及计算机化数据库在控制细菌耐药性方面的潜在作用。
Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S18-21. doi: 10.1086/503169.
10
Pharmacodynamic modeling of risk factors for ciprofloxacin resistance in Pseudomonas aeruginosa.铜绿假单胞菌对环丙沙星耐药危险因素的药效学建模
Infect Control Hosp Epidemiol. 2000 Jan;21(1 Suppl):S9-11. doi: 10.1086/503167.
Zotero 插件